Glaukos Corp(GKOS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.26 | Insider Own | 3.97% | Shs Outstand | 58.9M | Perf Week | 6.77% |
| Market Cap | 10.51B | Forward P/E | 340.74 | EPS next Y | 271.89% | Insider Trans | -6.95% | Shs Float | 56.6M | Perf Month | 15.44% |
| Enterprise Value | 10.33B | PEG | - | EPS next Q | -0.1 | Inst Own | 103.81% | Short Float | 6.8% | Perf Quarter | 17.8% |
| Income | -0.19B | P/S | 17.16 | EPS this Y | 66.18% | Inst Trans | 2.97% | Short Ratio | 4.35 | Perf Half Y | 46.04% |
| Sales | 0.61B | P/B | 15.37 | EPS next 5Y | - | ROA | -19.72% | Short Interest | 3.85M | Perf YTD | 57.89% |
| Book/sh | 11.6 | P/C | 36.73 | EPS past 3/5Y | -16.22% -3.95% | ROE | -25.98% | 52W High | -6.97% ($191.62) | Perf Year | 138.74% |
| Cash/sh | 4.85 | P/FCF | - | Sales past 3/5Y | 21.51% 17.67% | ROIC | -23.95% | 52W Low | 143.67% ($73.16) | Perf 3Y | 162.82% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -96.75% | Gross Margin | 79.12% | Volatility(W/M) | 3.39% 4.46% | Perf 5Y | 302.6% |
| Dividend TTM | - | EV/Sales | 16.86 | Sales Y/Y TTM | 41.55% | Oper. Margin | -12.89% | ATR (14) | 6.71 | Perf 10Y | 416.43% |
| Dividend Ex-Date | - | Quick Ratio | 4.46 | EPS Q/Q | 9.08% | Profit Margin | -30.68% | RSI (14) | 61.79 | Recom | 1.27 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.04 | Sales Q/Q | 49.54% | SMA20 | 6.2% ($167.86) | Beta | 0.75 | Target Price | $199.31 |
| Payout | - | Debt/Eq | 0.15 | Earnings | 2026/10/28 | SMA50 | 4.06% ($171.31) | Rel Volume | 1.2 | Prev Close | $178.88 |
| Employees | 1094 | LT Debt/Eq | 0.15 | EPS/Sales Surpr. | 33.49% 22.97% | SMA200 | 27.86% ($139.43) | Avg Volume(3M) | 0.89M | Price | $178.27 |
| IPO | 2015/6/25 | Option/Short | Yes/Yes | Trades | 13234 | Volume | 1,067,552 | Change | -0.34% |
This is a US-based ophthalmology-focused medical company that develops medical devices and therapeutics for the treatment of eye diseases. It develops and sells micro stents for glaucoma treatment, corneal disease therapies, and sustained-release drug delivery solutions. As a medical device stock, its performance is tied to procedure volumes, new product launches, and the expansion of new indications.
Over the past 1 year, on the higher side
7% below its 1-year high.
Traded about as much as usual. That is 120% of its average volume.
Next earnings report: October 28
1 days to go.
GKOS has a sound balance sheet but weak earning power
Of every $100 in sales, $12.89 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +66.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,716. Peers typically go for $248.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +302.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 103.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #14 of 141 in the industry
Based on market cap of $11B.
FAQ
What kind of company is GKOS?
GKOS belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of GKOS?
The market cap of GKOS is approximately $10.5B, ranking 882 within its sector.
What is the 52-week high and low for GKOS?
GKOS has recorded a 52-week high of $191.62 and a low of $73.16.
